CAR-T Cell Therapy Emerges as a Potential Cure for Autoimmune Diseases, Enabling Symptom-Free Lives

In recent years, CAR-T cell therapy has advanced from combating hematologic malignancies to a new medical frontier. As an immunotherapy that genetically engineers T cells to target and eliminate abnormal cells, CAR-T has demonstrated remarkable efficacy in patients with various cancers since its approval for cancer treatment in 2017.

Nowadays,Scientists have turned their attention to the field of autoimmune diseases.A growing body of research indicates that CAR-T cell therapy not only helps patients with refractory autoimmune diseases, such as ulcerative colitis, rheumatoid arthritis, and systemic lupus erythematosus, to alleviate or even eliminate symptoms, but may also completely reset abnormal immune responses.

Over the past three years,More than a dozen clinical trials from around the world have shown positive results,This therapy is poised to become a new standard of care for treating a variety of immune system-related diseases.

The core of CAR-T cell therapy lies inActivation and Customization of T CellsThis pioneer among immune cells. During the treatment process, T cells are first extracted from the patient’s body and genetically engineered to express a special protein called “chimeric antigen receptor (CAR)” on their surface; these modified T cells are then reinfused into the patient, where they can precisely identify and target B cells expressing specific antigens.

In various autoimmune diseases, B cells produce abnormal antibodies that attack the body’s own tissues. Therefore, CAR-T cells can fundamentally reshape the immune system by eliminating these aberrant B cells, creating space for the development of new, healthy B cells, thereby holding promise for achieving durable disease remission or even functional cure.

Since 2021,CAR-T Therapy Achieves Breakthrough Progress in the Field of Autoimmune Diseases, a 20-year-old patient with severe systemic lupus erythematosus (SLE) in Germany became the first case worldwide to receive this innovative immunotherapy.

David Simon, a clinical investigator involved in the treatment from Charité University Hospital in Berlin, who specializes in rheumatoid arthritis research, stated that since 2021, CAR-T therapy has been applied in Phase I and II clinical trials for various autoimmune diseases, includingSystemic Sclerosis, Myositis, Rheumatoid Arthritisetc. Currently, regardingSystemic Lupus Erythematosus and Myasthenia GravisPhase III clinical trials are also underway for (an autoimmune disease that can affect multiple muscle groups involved in respiration, swallowing, and vision).

David Simon stated that in CAR-T cell therapy trials for rheumatoid arthritis and systemic lupus erythematosus,The patient appears to be "cured."“They lost the autoantibodies that trigger the disease and no longer exhibit any symptoms, a novel phenomenon never before observed.”

Ulcerative ColitisIt is a disease affecting the colon, causing abdominal pain, ulcers, and bloody diarrhea, and is one of the latest conditions for which CAR-T cell therapy has shown therapeutic promise.。

In September 2024, gastroenterologist Markus Neurath and his colleagues at University Hospital Erlangen in Germany reported a case involving the use of CAR-T cell therapy to treat a 21-year-old woman with ulcerative colitis. Following treatment, she exhibitedSigns of Remission Lasting 14 Weeks, No Longer Requiring Pharmacological Treatment, and be able to return to work.

“The results were quite encouraging,” said Neurath. His team plans to test the therapy in a larger cohort before proceeding to controlled clinical trials involving more participants.

In the field of donor-derived CAR T cells, immunologist Bing Du and his team at East China Normal University published the results of a pilot study earlier in 2024, which utilized donor-derived immune cells to treat refractory systemic lupus erythematosus.

Unlike traditional autologous CAR-T therapy (which involves extracting T cells from the patient for modification), donor-derived CAR-T cells utilize T cells from healthy donors. ThisOff-the-shelf(off-the-shelf) CAR-T therapy can be manufactured and stored in advance like conventional pharmaceuticals, enabling large-scale production. This approach significantly shortens manufacturing lead times and substantially reduces costs, thereby allowing more patients to access treatment in a timely manner.

As part of the latest research, four women with systemic lupus erythematosus (SLE) affecting multiple organs underwent chemotherapy to reduce white blood cell counts, followed by an infusion of donor-derived CAR-T cells. Three months later, these women no longer exhibited symptoms such as arthritis, vascular swelling, and hair loss; one patient achieved remission and no longer required any medication, while the other three received low-dose steroids as maintenance therapy.

Du Bing stated that the trial results“Even better than we imagined”, which may be because CAR-T cells triggered the complete elimination of dysfunctional B cells that attack the body’s tissues. “The immune system not only reset the B cells but also reset the rest of the immune system,” he added, suggesting that this could allow new, healthy B cells to replace the dysfunctional ones.

Other research teams are also attempting to develop methods that enable patients to generate CAR-T cells in vivo, thereby avoiding the time-consuming and costly manufacturing process, as well as the risks of infection and toxicity associated with the immunosuppressive therapy patients must undergo prior to receiving CAR-T cell therapy. “These are early-stage developments, butThis marks the beginning of a new era in clinical medicine.“Neurath said.

Neurath stated,CAR-T cell therapy will become a more common treatment in the coming years,This includes applications for other chronic autoimmune diseases. “For systemic lupus erythematosus, I am quite confident that this will become a standard therapy, as many prospective trials are underway and numerous independent research teams have reported strikingly positive results,” he added.

Although multiple patients have achieved remission following CAR-T therapy, Simon stated that it remains difficult to determine whether CAR-T cell therapy constitutes a permanent cure. “For systemic lupus erythematosus, what we are currently observing is,”This may be a curative therapy,“At least in a large number of patients,” he added. But for less-studied diseases, such as rheumatoid arthritis, it is still too early to draw conclusions.

It can be said that the application of CAR-T cell therapy in the field of autoimmune diseases represents a significant advance in precision medicine. From the first successful case in 2021 to the positive results of multiple clinical trials today, this therapy is bringing new hope to patients with autoimmune diseases. Although more research is needed to determine its long-term efficacy and safety, early results have already demonstrated substantial therapeutic potential.